Starting with the PDE2A enzyme, the radioligand [18F]4 ([18F]PF-05270430) has been further evaluated to confirm its suitability for target occupancy examinations in the assessment of novel PDE2A inhibitors as therapeutics for neuropsychiatric and neurodegenerative diseases [21]. Here, PDE2A is linked to neurodegenerative disease.